Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoramidic Acid SCHEMBL312721 | 0.94 | MAPT (0.45) | MAPTNOS1POLBMAOBALOX15 | |
| SCHEMBL28686 | 0.92 | MAPT (0.54) | MAPTNOS1POLBMAOBALOX15 | |
| SCHEMBL30597526 | 0.92 | MAPT (0.54) | MAPTNOS1POLBMAOBALOX15 | |
| Methane SCHEMBL27929615 | 0.90 | MAPT (0.53) | MAPTNOS1POLBMAOBALOX15 | |
| Ammonia Solution, Strong SCHEMBL28394313 | 0.90 | MAPT (0.53) | MAPTNOS1POLBMAOBALOX15 | |
| Triphosphate SCHEMBL594275 | 0.89 | CA1 (0.44) | MAPTNOS1POLBMAOBALOX15 | |
| Acetic Acid SCHEMBL28007455 | 0.86 | POLB (0.48) | MAPTNOS1POLBMAOBALOX15 | |
| SCHEMBL21359704 | 0.86 | MAPT (0.46) | MAPTNOS1POLBMAOBALOX15 | |
| Acrylic Acid SCHEMBL29048066 | 0.82 | MAPT (0.43) | MAPTNOS1POLBMAOBALOX15 | |
| Propionic Acid SCHEMBL27602614 | 0.82 | POLB (0.45) | MAPTNOS1POLBMAOBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8981078-B2 | Selective inhibitors of translesion DNA replication | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130004945-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | BERDIS ANTHONY J (US) | 2013-01-03 | — | — | US | disclosed |
| US-8114847-B2 | Selective inhibitors of translesion DNA replication | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090048202-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | CASE WESTERN RESERVE UNIVERSITY | 2009-02-19 | — | — | US | disclosed |
| WO-2006101911-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | CASE WESTERN RESERVE UNIVERSITY (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048202-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | REV1, PCNA, DNA2 | MAPT 3719/4885NOS1 2974/4885POLB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.